Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine
详细信息 查看全文
- 作者：Linping Hu (1) (6)
Kun Ru (1) (2)
Li Zhang (1) (3)
Yuting Huang (4)
Xiaofan Zhu (1) (3) (6)
Hanzhi Liu (1) (6)
Anders Zetterberg (5)
Tao Cheng (1) (6)
Weimin Miao (1) (6) - 关键词：Fluorescence in situ hybridization (FISH) ; Solid tumors ; Hematopoietic malignancies ; Genetic aberrations ; Biomarkers ; Personalized medicine
- 刊名：Biomarker Research
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：2
- 期：1
- 全文大小：456 KB
- 作者单位：Linping Hu (1) (6)
Kun Ru (1) (2)
Li Zhang (1) (3)
Yuting Huang (4)
Xiaofan Zhu (1) (3) (6)
Hanzhi Liu (1) (6)
Anders Zetterberg (5)
Tao Cheng (1) (6)
Weimin Miao (1) (6)
1. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
6. Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing Road 288, Tianjin, 300020, P.R. China
2. Department of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3. Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin, China
5. Department of Oncology-Pathology and Karolinska Cancer Center, Karolinska Institute, Stockholm, Sweden - ISSN：2050-7771
文摘
Extensive studies of the genetic aberrations related to human diseases conducted over the last two decades have identified recurrent genomic abnormalities as potential driving factors underlying a variety of cancers. Over the time, a series of cutting-edge high-throughput genetic tests, such as microarrays and next-generation sequencing, have been developed and incorporated into routine clinical practice. Although it is a classical low-throughput cytogenetic test, fluorescence in situ hybridization (FISH) does not show signs of fading; on the contrary, it plays an increasingly important role in detecting specific biomarkers in solid and hematologic neoplasms and has therefore become an indispensable part of the rapidly developing field of personalized medicine. In this article, we have summarized the recent advances in FISH application for both de novo discovery and routine detection of chromosomal rearrangements, amplifications, and deletions that are associated with the pathogenesis of various hematopoietic and non-hematopoietic malignancies. In addition, we have reviewed the recent developments in FISH methodology as well.